Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

BACKGROUND: Immune checkpoint inhibitors and chemotherapy can synergistically increase efficacy in a variety of malignancies. We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellul...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Qin, Shukui, Liu, Ying, Chen, Zhendong, Ren, Zhenggang, Xiong, Jianping, Meng, Zhiqiang, Zhang, Xiao, Wang, Linna, Zhang, Xiaojing, Zou, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106453/
https://www.ncbi.nlm.nih.gov/pubmed/33976538
http://dx.doi.org/10.2147/DDDT.S304857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106453/
https://www.ncbi.nlm.nih.gov/pubmed/33976538
http://dx.doi.org/10.2147/DDDT.S304857

Ejemplares similares